What is the fine-grained topic of the following text: The lead compound of Ogeda (formerly Euroscreen S.A.), fezolinetant (ESN364), is currently being developed in three Phase IIa programmes to treat different conditions: menopausal hot flashes, polycystic ovary syndrome (PCOS) and uterine fibroids. Only return the topic.
The development and testing of the drug fezolinetant (ESN364) for treating menopausal hot flashes, polycystic ovary syndrome, and uterine fibroids.